Trial Profile
A Double Blind, Placebo-controlled, Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Dravet syndrome
- Focus Adverse reactions; Registrational
- Acronyms GWPCARE1
- Sponsors GW Pharmaceuticals
- 05 Dec 2016 According to a GW Pharmaceuticals media release, data from this trial presented at the 70th Annual Meeting of the American Epilepsy Society 2016.
- 05 Dec 2016 Results published in the GW Pharmaceuticals Media Release
- 26 Sep 2016 According to a GW Pharmaceuticals media release, the company plans to submit a NDA for cannabidiol (Epidiolex) to the US FDA in the first half of 2017.